litlas
Log inCreate account

Daniel H. Present

Active 1972–2011

41
Papers
22,259
Citations
41
h-index
41
i10-index

Citations

Citations per year for Daniel H. Present1973: 1 citations1974: 2 citations1975: 5 citations1976: 3 citations1978: 1 citations1979: 3 citations1980: 3 citations1981: 1 citations1982: 4 citations1983: 2 citations1984: 1 citations1985: 3 citations1986: 5 citations1988: 2 citations1989: 11 citations1990: 20 citations1991: 17 citations1992: 7 citations1993: 9 citations1994: 8 citations1995: 21 citations1996: 18 citations1997: 11 citations1998: 36 citations1999: 102 citations2000: 137 citations2001: 148 citations2002: 204 citations2003: 221 citations2004: 191 citations2005: 203 citations2006: 291 citations2007: 286 citations2008: 267 citations2009: 225 citations2010: 277 citations2011: 230 citations2012: 159 citations2013: 247 citations2014: 204 citations2015: 205 citations2016: 174 citations2017: 151 citations2018: 127 citations2019: 451 citations2020: 400 citations2021: 300 citations2022: 233 citations2023: 188 citations2024: 246 citations2025: 121 citations2026: 5 citations1977: no citations, so this year is not shown1987: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,785 citing papers, 23.5% of this breakdownUnited Kingdom: 606 citing papers, 8% of this breakdownCanada: 543 citing papers, 7.1% of this breakdownItaly: 441 citing papers, 5.8% of this breakdownGermany: 425 citing papers, 5.6% of this breakdownFrance: 415 citing papers, 5.5% of this breakdownBelgium: 338 citing papers, 4.4% of this breakdownNetherlands: 308 citing papers, 4.1% of this breakdownJapan: 256 citing papers, 3.4% of this breakdownSpain: 246 citing papers, 3.2% of this breakdownChina: 222 citing papers, 2.9% of this breakdownAustralia: 192 citing papers, 2.5% of this breakdown
0%23.5%Other 24%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology60.8%
  • Medicine28.2%
  • Immunology and Microbiology7.8%
  • Neuroscience1.1%
  • Nursing0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Other1.2%

Topics

  • Inflammatory Bowel Disease24%
  • Microscopic Colitis9.2%
  • Rheumatoid Arthritis Research and Therapies4.3%
  • Autoimmune and Inflammatory Disorders4.2%
  • Biosimilars and Bioanalytical Methods2.4%
  • Pregnancy and Medication Impact1.9%
  • Other54%

Coauthors

All papers

Open in search
  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel - New England Journal of Medicine 2005 cited by 3,883

  2. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

    Authors: Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer, Lloyd Mayer, Daniel H. Present, Tanja Braakman, Kimberly L. DeWoody, T Schaible, Paul Rutgeerts - New England Journal of Medicine 1997 cited by 3,160

  3. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

    Authors: Daniel H. Present, Paul Rutgeerts, Stephan Targan, Stephen B. Hanauer, Lloyd Mayer, R. A. van Hogezand, Daniel K. Podolsky, Bruce E. Sands, Tanja Braakman, Kimberly L. DeWoody, T Schaible, Sander J. H. van Deventer - New England Journal of Medicine 1999 cited by 2,747

  4. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

    Authors: Jean‐Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, Dirk Eßer, Yanxin Wang, Yinghua Lang, Colleen Marano, Richard Strauß, B.J. Oddens, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Daniel H. Present, Bruce E. Sands, William J. Sandborn - Gastroenterology 2011 cited by 919

  5. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

    Authors: William J. Sandborn, Brian G. Feagan, Stephen B. Hanauer, Herbert Lochs, Robert Löfberg, R Modigliani, Daniel H. Present, Paul Rutgeerts, Jürgen Schölmerich, Eduard F. Stange, Lloyd R. Sutherland - Gastroenterology 2002 cited by 684

  6. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

    Authors: Paul Rutgeerts, Geert D’Haens, Stephan R. Targan, Eric Vasiliauskas, Stephen B. Hanauer, Daniel H. Present, Lloyd Mayer, R. A. van Hogezand, Tanja Braakman, Kimberly L. DeWoody, T Schaible, Sander J. H. van Deventer - Gastroenterology 1999 cited by 1,095

  7. Anti–Interleukin-12 Antibody for Active Crohn's Disease

    Authors: Peter Mannon, Ivan J. Fuss, Lloyd Mayer, Charles O. Elson, William J. Sandborn, Daniel H. Present, Ben J. Dolin, Nancy Goodman, Catherine Groden, Ronald L. Hornung, Martha Quezado, Markus F. Neurath, Jochen Salfeld, Geertruida M. Veldman, Ullrich Schwertschlag, Warren Strober - New England Journal of Medicine 2004 cited by 854

  8. Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    Authors: Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul Rutgeerts, Zsolt Tulassay, Miroslava Volfová, Douglas C. Wolf, C. Hernandez, Jeffrey D. Bornstein, William J. Sandborn - Gastroenterology 2007 cited by 614

  9. Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial

    Authors: James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret A. Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu - Gastroenterology 2008 cited by 226

  10. Treatment of Crohn's Disease with 6-Mercaptopurine

    Authors: Daniel H. Present, Burton I. Korelitz, Nathaniel Wisch, Joseph L. Glass, David B. Sachar, Bernard S. Pasternack - New England Journal of Medicine 1980 cited by 1,048

  11. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial

    Authors: Stephen B. Hanauer, Burton I. Korelitz, Paul Rutgeerts, Mark A. Peppercorn, Ronald A. Thisted, Russell D. Cohen, Daniel H. Present - Gastroenterology 2004 cited by 468

  12. Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

    Authors: Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Marion Blank, Yinghua Lang, Jewel Johanns, Jean‐Frédéric Colombel, Daniel H. Present, Bruce E. Sands - Inflammatory Bowel Diseases 2011 cited by 208

  13. Cyclosporine and Infliximab as Rescue Therapy for Each Other in Patients With Steroid-Refractory Ulcerative Colitis

    Authors: Elana Maser, Deepthi Deconda, Simon Lichtiger, Thomas Ullman, Daniel H. Present, Asher Kornbluth - Clinical Gastroenterology and Hepatology 2008 cited by 182

  14. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

    Authors: William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel - Gastroenterology 2009 cited by 472

  15. Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trial

    Authors: William J. Sandborn, Daniel H. Present, Kim L. Isaacs, Douglas C. Wolf, Eugene Greenberg, Stephen B. Hanauer, Brian G. Feagan, Lloyd Mayer, Therese Johnson, Joseph A. Galanko, Christopher F. Martin, Robert S. Sandler - Gastroenterology 2003 cited by 334

  16. The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients

    Authors: David N. Moskovitz, Carol Bodian, Mark L. Chapman, James F. Marion, Peter Rubin, Ellen Scherl, Daniel H. Present - The American Journal of Gastroenterology 2004 cited by 204

  17. Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease

    Authors: Michael Sternthal, Seamus Murphy, James George, Asher Kornbluth, Simon Lichtiger, Daniel H. Present - The American Journal of Gastroenterology 2008 cited by 125

  18. 6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity

    Authors: Daniel H. Present, Stephen J. Meltzer, Michael P. Krumholz, Anita Wolke, Burton I. Korelitz - Annals of Internal Medicine 1989 cited by 737

  19. Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial

    Authors: James F. Marion, Jerome D. Waye, Daniel H. Present, Yuriy Israel, Carol Bodian, Noam Harpaz, Mark L. Chapman, Steven H. Itzkowitz, Adam F. Steinlauf, María T. Abreu, Thomas Ullman, James Aisenberg, Lloyd Mayer - The American Journal of Gastroenterology 2008 cited by 288

  20. Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study

    Authors: Kim L. Isaacs, Robert S. Sandler, María T. Abreu, Michael F. Picco, Stephen B. Hanauer, Stephen J. Bickston, Daniel H. Present, Francis A. Farraye, Douglas C. Wolf, William J. Sandborn - Inflammatory Bowel Diseases 2007 cited by 118

  21. Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel Disease

    Authors: Steven H. Itzkowitz, Daniel H. Present - Inflammatory Bowel Diseases 2005 cited by 569

  22. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps

    Authors: Peter Rubin, Sonia Friedman, Noam Harpaz, Eric S. Goldstein, Jeffrey N. Weiser, Jeremy Schiller, Jerome D. Waye, Daniel H. Present - Gastroenterology 1999 cited by 357

  23. Screening and surveillance colonoscopy in chronic Crohn's colitis

    Authors: Sonia Friedman, Peter Rubin, Carol Bodian, Eric S. Goldstein, Noam Harpaz, Daniel H. Present - Gastroenterology 2001 cited by 250

  24. The state of the art in the management of inflammatory bowel disease.

    Authors: Stephen B. Hanauer, Daniel H. Present - 2003 cited by 165